Nomic develops a proteomic technology platform to understand, detect, and treat diseases with DNA nanotechnology.
Nomic has raised $42.0M in total funding. The most recent round was Series B. The last funding was announced in September 2024.
Nomic's investors include Y Combinator, Lux Capital, SR One, Avant Bio, First Star Ventures.
Nomic is headquartered in Montréal, Canada.
Nomic develops a proteomic technology platform to understand, detect, and treat diseases with DNA nanotechnology.
Nomic is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Nomic — Funding & Investors." VCBacked, September 17, 2024, https://www.vcbacked.co/company/nomic. Accessed October 17, 2026.
VCBacked. (2024). Nomic — Funding & Investors. Retrieved October 17, 2026, from https://www.vcbacked.co/company/nomic
{{cite web |title=Nomic — Funding & Investors |url=https://www.vcbacked.co/company/nomic |website=VCBacked |access-date=October 17, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated